The medical community is excited with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s showing significant potential in clinical trials for treating obesity. Unlike some current weight loss approaches, retatrutide appears to provide a more substantial decrease in body mass and enhance metabolic markers, particu